Facchinetti Francesco, Bordi Paola, Leonetti Alessandro, Buti Sebastiano, Tiseo Marcello
Medical Oncology Unit, University Hospital of Parma, Parma, Italy,
Drug Des Devel Ther. 2018 Sep 10;12:2857-2873. doi: 10.2147/DDDT.S124380. eCollection 2018.
Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-small-cell lung cancer (NSCLC) patients. Atezolizumab, an anti-PD-L1 agent, figures among the drugs that provide previously unenvisaged outcomes in the pretreated setting of metastatic NSCLC. Increasing evidence vouches for the early administration of PD-1/PD-L1 blockers in untreated patients, encompassing atezolizumab combinations with chemotherapy and the anti-angiogenic agent bevacizumab. Moreover, the development of atezolizumab allowed to derive several hints regarding clinical and immunological factors predictive of its activity and efficacy, some of them exclusive among this class of drugs. This review provides an overview of atezolizumab development throughout clinical trials toward its applicability in the routine practice, with a particular focus on patient selection based on clinical and immune-related factors.
程序性细胞死亡蛋白1/程序性死亡配体1（PD-1/PD-L1）阻断疗法已成为晚期非小细胞肺癌（NSCLC）患者治疗中的既定现实。阿替利珠单抗是一种抗PD-L1药物，在转移性NSCLC的预处理治疗中，它是能带来前所未有的治疗效果的药物之一。越来越多的证据支持在未治疗的患者中早期使用PD-1/PD-L1阻断剂，包括阿替利珠单抗与化疗以及抗血管生成药物贝伐单抗的联合使用。此外，阿替利珠单抗的研发让人们获得了一些关于预测其活性和疗效的临床及免疫因素的线索，其中一些线索在这类药物中是独有的。本综述概述了阿替利珠单抗在整个临床试验中的研发情况及其在常规临床实践中的适用性，特别关注基于临床和免疫相关因素的患者选择。
